Aurinia Pharmaceuticals has reported positive interim results from the AURORA 2 continuation study of Lupkynis (voclosporin) to treat lupus nephritis (LN).

The structurally modified calcineurin inhibitor (CNI) Lupkynis is intended to treat adult patients with LN, which is a serious manifestation of systemic lupus erythematosus (SLE).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The randomised, double-blind, placebo-controlled Phase III AURORA 2 clinical trial is evaluating the tolerability and safety of the oral medicine to treat LN in patients with SLE, a complex chronic autoimmune disease.

Participants who have completed a one-year treatment during the Phase III AURORA 1 trial were eligible for enrolment in the AURORA 2 continuation study.

In this study, the LN patients were given 23.7mg voclosporin or placebo in combination with 1g mycophenolate mofetil twice a day for 24 additional months.

According to the interim analysis, around 216 patients continued into the AURORA 2 study and received total treatment for 30 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was observed that the patients in the LN group who received Lupkynis sustained meaningful reductions in proteinuria with a stable estimated glomerular filtration rate (eGFR) at 30 months.

Furthermore, lupkynis showed sustained safety and tolerability compared to placebo.

Aurinia Pharmaceuticals chief medical officer Neil Solomons said: “We are encouraged to see the continued positive outcomes with Lupkynis and look forward to seeing and presenting the complete results from AURORA 2 in the coming months.”

The final results of the AURORA 2 continuation study are anticipated to be released by the end of this year.

In May 2021, Aurinia reported positive results from a Phase III AURORA 1 study of oral therapy Lupkynis in adult patients with LN.